Rita Monterubbianesi
Rome, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications
Effectiveness and Safety of Risankizumab in Crohn Disease After Failure of a First Line of Advanced Therapy: A Long-Term, Real-Life Study.
Journal: American journal of therapeutics
Published: July 23, 2026
Effectiveness and Safety of Risankizumab in Crohn Disease After Failure of a First Line of Advanced Therapy: A Long-Term, Real-Life Study.
Journal: American journal of therapeutics
Published: July 23, 2026
Comparative Effectiveness and Safety of Tofacitinib, Filgotinib, and Upadacitinib in Ulcerative Colitis: A Multicenter Real-World Cohort Study.
Journal: Advances in therapy
Published: February 11, 2026
Upadacitinib's Effectiveness and Safety as a Second- or Third-Line Therapy in Patients with Ulcerative Colitis: Data from a Real-World Study.
Journal: Journal of clinical medicine
Published: August 27, 2025
Long-Term Effectiveness and Safety of Ustekinumab in Crohn's Disease: Results from a Large Real-Life Cohort Study.
Journal: Journal of clinical medicine
Published: September 23, 2024
Ustekinumab safety and effectiveness in patients with ulcerative colitis: results from a large real-life study.
Journal: Expert opinion on biological therapy
Published: January 22, 2024
The Earlier You Find, the Better You Treat: Red Flags for Early Diagnosis of Inflammatory Bowel Disease.
Journal: Diagnostics (Basel, Switzerland)
Published: September 11, 2023
Use of tofacitinib as first or second-line therapy is associated with better outcomes in patients with ulcerative colitis: data from a real-world study.
Journal: Expert opinion on pharmacotherapy
Published: June 26, 2023
Real-world efficacy and safety of vedolizumab in managing ulcerative colitis versus Crohn's disease: results from an Italian multicenter study.
Journal: Expert opinion on biological therapy
Published: February 27, 2023
Current practice for upper gastrointestinal endoscopy: a multicentre study in Lazio, Italy.
Journal: Journal of gastrointestinal and liver diseases : JGLD
Published: February 24, 2023
SARS-CoV-2 infection in patients with inflammatory bowel disease: comparison between the first and second pandemic waves.
Journal: BMC gastroenterology
Published: September 28, 2022
Replacement of Adalimumab Originator to Adalimumab Biosimilar for a Non-Medical Reason in Patients with Inflammatory Bowel Disease: A Real-life Comparison of Adalimumab Biosimilars Currently Available in Italy.
Journal: Journal of gastrointestinal and liver diseases : JGLD
Published: September 08, 2022
Last Updated: 09/26/2026